πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9346829

5-HT3 receptor antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9339528

Methods for treating epithelium trauma of the intestinal mucosa using interleukin-1 recept

GENERAL REGENERATIVES, LTD. Β· Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9340594

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9334495

Minor groove binder (MGB)-oligonucleotide miRNA antagonists

ELITECHGROUP B.V. Β· Granted Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9315463

Cyclohexylamine derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist acti

Almirall, S.A. Β· Granted Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9315568

Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders

ADHERON THERAPEUTICS, INC. Β· Granted Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9303045

5-HT3 receptor antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9303258

Method and compositions comprising small RNA agonist and antagonists to modulate inflammat

The Regents of the University of California Β· Granted Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9302120

Spiro-oxindole MDM2 antagonists

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9283183

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9283220

Compositions of opioid antagonists and methods for treating conditions caused by the varic

IMUNEKS FARMA ILAC SANAYI VE TICARET ANONIM SIRKETI PAK IS MERKEZI Β· Granted Tue Mar 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9277748

Agonist/antagonist compositions and methods of use

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Mar 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9273093

Ξ±4Ξ²7 peptide dimer antagonists

Protagonist Therapeutics, Inc. Β· Granted Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9272990

Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis

AMIRA PHARMACEUTICALS, INC. Β· Granted Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9260504

N- and C-terminal substituted antagonistic analogs of GH-RH

THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS Β· Granted Tue Feb 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9254338

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9233162

High affinity VEGF-receptor antagonists

The Board of Regents of the University of Texas System Β· Granted Tue Jan 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9233108

Cyclohexylamine derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist acti

Almirall, S.A. Β· Granted Tue Jan 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9216971

Quaternary ammonium compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Dec 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9206172

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9206154

Inverse agonists and neutral antagonists for the TSH receptor

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9199993

8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9193790

Use of antagonists of the interaction between HIV GP120 and A4B7 integrin

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9181253

Adenosine receptor agonists, partial agonists, and antagonists

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Nov 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted